Skip to main content

Table 2 Correlation of AURKA expression and clinicopathologic characteristics in the datasheet of GSE31684

From: Increased AURKA promotes cell proliferation and predicts poor prognosis in bladder cancer

Characteristic

n

AURKA expression (%)

Pearson χ2

P

High

Low or no

Total

93

70 (75.27)

23 (24.73)

  

Age

   

2.596

0.122

 ≥ 65

65

52 (80.00)

13 (20.00)

  

 < 65

28

18 (64.29)

10 (35.71)

  

Gender

   

0.010

1.000

 Female

25

19 (76.00)

6 (24.00)

  

 Male

68

51 (75.00)

17 (25.00)

  

RC stage

   

18.766

0.001**

 pTa

5

0 (0.00)

5 (100.00)

  

 pT1

10

6 (60.00)

4 (40.00)

  

 pT2

17

13 (76.47)

4 (23.53)

  

 pT3

42

35 (83.33)

7 (16.67)

  

 pT4

19

16 (84.21)

3 (15.79)

  

RC grade

   

11.833

0.003**

 high

87

69 (78.16)

18 (21.84)

  

 low

6

1 (16.67)

5 (83.33)

  

Histology

   

2.487

0.288

 TCC

86

63 (73.25)

23 (26.75)

  

 TCC/CIS

2

2 (100.00)

0 (0.00)

  

 TCC/square

5

5 (100.00)

0 (0.00)

  

Lymph node status

   

5.876

0.053

 PN0

49

32 (65.31)

17 (34.69)

  

 PN+

28

25 (89.28)

3 (10.72)

  

 PNx

16

13 (81.25)

3 (18.75)

  

Recurrence

   

0.304

0.635

 No

52

38 (73.08)

14(26.92)

  

 Yes

41

32 (78.05)

9 (21.95)

  

Last known status

   

2.651

0.266

 NED

28

18 (64.28)

10 (35.72)

  

 DOC

27

22 (81.48)

5 (18.52)

  

 DOD

38

30 (78.95)

8 (21.05)

  

Metastasis

   

0.199

0.806

 No

57

42 (73.68)

15 (26.32)

  

 Yes

36

28 (77.78)

8 (22.22)

  
  1. **P<0.01 significant difference between clinicopathologic characteristics of patients with high and low AURKA expression